Tenaya therapeutics announces 2025 strategic priorities and anticipated milestones

Continued focus on driving advancement of tn-201 and tn-401 gene therapies  for cardiomyopathies dosing initiated in cohort 2 of the mypeak™-1 phase 1b/2 clinical trial of tn-201 for treatment of mybpc3-associated hypertrophic cardiomyopathy additional cohort 1 data to be reported in 1h25 building on promising initial data initial data from ridge™-1 phase 1b clinical trial of tn-401 for pkp2-associated arrhythmogenic right ventricular cardiomyopathy expected in 2h25 south san francisco, calif., jan. 13, 2025 (globe newswire) -- tenaya therapeutics, inc. (nasdaq: tnya), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today provided an update on its clinical development programs and outlined its strategic priorities for 2025.
TNYA Ratings Summary
TNYA Quant Ranking